STOCK TITAN

Acrivon Therapeutics: 107 shares sold for tax withholding

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) Chief Accounting Officer Katharine Peterson had 107 shares sold automatically upon restricted-stock-unit vesting to satisfy mandatory tax withholding on November 17, 2026. The reported $1.45 per-share price was the weighted average for a broker’s sale of 4,070 shares for a group of employees, including Peterson; proceeds were allocated among the employees pro rata. She held 17,926 shares directly after the sale. No Rule 10b5-1 plan is reported.

Insider Peterson Katharine
Role Chief Accounting Officer
Sold 107 shs ($155.15)
Type Security Shares Price Value
Sale Common Stock F1, F2 107 $1.45 $155.15
Holdings After Transaction: Common Stock — 17,926 shares (Direct)
Footnotes (2)
  1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
  2. F2. The price reported in Column 4 above reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.
Shares sold 107 shares Automatically sold for mandatory tax withholding upon restricted-stock-unit vesting on November 17, 2026.
Weighted average price $1.45 per share Weighted average for the broker’s sale of 4,070 shares for employee withholding, including Peterson.
Employee-group broker sale 4,070 shares Shares sold by a broker to satisfy withholding tax liability for a group of employees, including Peterson.
Direct shares held after sale 17,926 shares Peterson’s reported direct holdings following the transaction.
restricted stock units technical
"upon vesting of restricted stock units"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average price financial
"reflects the weighted average price of 4,070 shares sold"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ACRV shares did Chief Accounting Officer Katharine Peterson sell?

Katharine Peterson had 107 shares sold automatically for mandatory tax withholding on November 17, 2026, upon restricted stock unit vesting. The reported $1.45 per-share price was the weighted average for a broker’s sale of 4,070 shares for employees including Peterson; proceeds were allocated pro rata. She held 17,926 shares directly afterward. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Peterson Katharine

(Last)(First)(Middle)
C/O ACRIVON THERAPEUTICS, INC.
480 ARSENAL WAY, SUITE 100

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Accounting Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026S(1)107D$1.45(2)17,926D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.
2. The price reported in Column 4 above reflects the weighted average price of 4,070 shares sold by a broker on November 17, 2026, to satisfy the payment of withholding tax liability of a group of employees of the Issuer, including the reporting person. The proceeds of all such sales were allocated to the employees, including the reporting person, on a pro rata basis.
/s/ Adam D. Levy, Attorney-in-Fact11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading